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ABSTRACT: Familial cerebral cavernous malformations type III (fCCM3) is a disease of the cerebrovascular system
causedby loss-of-functionmutations in ccm3 that result in dilated capillarybeds that are susceptible tohemorrhage.
Before hemorrhage, fCCM3 lesions are characterized by a hyperpermeable blood-brain barrier (BBB), the key
pathologic feature of fCCM3. We demonstrate that connexin 43 (Cx43), a gap junction (GJ) protein that is in-
corporated into theBBB junction complex, is up-regulated in lesionsof amurinemodelof fCCM3. Small interfering
RNA–mediated ccm3 knockdown (CCM3KD) in brain endothelial cells in vitro increased Cx43 protein expression,
GJplaque size,GJ intracellular communication (GJIC), andbarrier permeability. CCM3KDhyperpermeabilitywas
rescued by GAP27, a peptide gap junction and hemichannel inhibitor of Cx43 GJIC. Tight junction (TJ) protein,
zonula occludens 1 (ZO-1), accumulated at Cx43 GJs in CCM3KD cells and displayed fragmented staining at TJs.
The GAP27-mediated inhibition of Cx43 GJs in CCM3KD cells restored ZO-1 to TJ structures and reduced plaque
accumulation at Cx43 GJs. The TJ protein, Claudin-5, was also fragmented at TJs in CCM3KD cells, and GAP27
treatment lengthened TJ-associated fragments and increased Claudin 5–Claudin 5 transinteraction. Overall, we
demonstrate that Cx43GJs are aberrantly increased in fCCM3 and regulate barrier permeability by a TJ-dependent
mechanism.—Johnson,A.M.,Roach, J. P.,Hu,A., Stamatovic, S.M.,Zochowski,M.R.,Keep,R.F.,Andjelkovic,A.V.
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Familial cerebral cavernous malformations type III
(fCCM3) is a disease that affects cerebrovascular capillary
beds. Patients carry a null mutation in one allele of ccm3
(pdcd10).Lesions—characterizedbydilatedvessels, blood-
filled caverns, loss of contact between endothelial cells,
and insufficient blood-brain barrier (BBB) integrity—are
initiated upon acquiring a mutation in the second ccm3
allele that causes a loss of functional CCM3 protein. Im-
paired BBB integrity is considered the primary cause of
fCCM3 morbidities, including seizures, focal neurologic
deficits, and cerebral hemorrhage (1). No effective treat-
ment is available to patients with fCCM3, and therapeutic
development is hindered by a lack of a thorough un-
derstanding of CCM3-dependent pathways. Proteomic
analysis has revealed that 80% of CCM3 is bound to the
striatin-interacting phosphatase and kinase (STRIPAK)
complex (2). This complex contains many phosphatases
and kinases that produce wide-ranging cellular effects,
including Golgi apparatus development, calcium sensing,
and, most recently, a CCM3-dependent effect on actin cy-
toskeleton organization that ismediated by cortactin (3, 4).
BBB integrity is maintained by a unique junction
complex at the endothelial–endothelial border that
ABBREVIATIONS: BBB, blood-brain barrier; CCM3KD, small interfering
RNA–mediated ccm3 knockdown; Cx, connexin; Cx43, connexin 43;
fCCM3, familial cerebral cavernous malformations type III; FRAP, fluo-
rescence recovery after photobleaching; FRET, fluorescence resonance
energy transfer; GAP19, Cx43 hemichannel inhibitor; GAP27, Cx43 gap
junction and hemichannel inhibitor; Gd-DTPA, gadolinium-DTPA; GJ,
gap junction; GJIC, gap junction intercellular communication; HC, hemi-
channel; LY, Lucifer yellow; mBEC, microvascular brain endothelial cell;
ROI, region of interest; siRNA, small interfering RNA; STRIPAK, striatin-
interacting phosphatase and kinase; TE, echo time; TEER, transendothelial
electrical resistance; TJ, tight junction; TR, repetition time; ZO-1, zonula
occludens 1
1 Correspondence: Department of Pathology, University of Michigan,
Medical School, 7520A MSRB I, 1150 W Medical Center Dr., Ann Arbor,
MI 48109-5602, USA. E-mail: anuskaa@med.umich.edu
doi: 10.1096/fj.201700699R
This article includes supplemental data. Please visit http://www.fasebj.org to
obtain this information.
0892-6638/18/0032-2615 © FASEB 2615
includes adherens junctions, tight junctions (TJs), and
gap junctions (GJs). Under normal physiologic condi-
tions, crosstalk mechanisms allow these complexes to
form a stable barrier that prevents paracellular perme-
ability. The TJ complex is composed of the trans-
membrane proteins, claudins and occludin, that form
transinteractions with neighboring cell claudins and
occludin and occlude the paracellular space. Claudins
and occludin are stabilized by intracellular adaptor
proteins, including zonula occludens 1 (ZO-1), that
tether them to the actin cytoskeleton. Analysis of
TJ proteins in lesions of patients with fCCM3 and in
vitro work has demonstrated a loss of TJ proteins
from the junctional complex of fCCM3 (4, 5). Mean-
while, whether adherens junctions, organized in a
similarmanner toTJswith transmembrane cadherins and
adapter proteins, are affected in fCCM3 is less clear (4, 6).
The final member of the BBB junction complex, the GJ,
has not been ascribed a regulatory role for paracellular
permeability. GJs are channel structures at adjacent cell
borders, are formed by members of the connexin family
(Cx), and allowdirect passage of ions and smallmolecules
that are ,1 kDa between the cytosols of adjacent cells.
Channels are formed by the aggregation of homo- or
hetero-hexameric Cx proteins (7). Cx family members
display tissue-specific expression, with Cx37, Cx40, and
Cx43 expressed in brain endothelia (8, 9). Aberrant ele-
vation of Cx43 protein has recently been shown to be
detrimental to barrier integrity, but whether this effect is
dependent on Cx43 GJs or other functions of Cx43, in-
cluding hemichannels (HCs) that do not directly oppose
another Cx43 channel, has not been thoroughly described
(10, 11).
We have identified that ccm3+/2p532/2mice, a murine
modelof fCCM3,haveelevatedCx43proteinexpression in
lesions. Analysis of Cx43 in CCM3 knockdown
(CCM3KD) brain endothelial cells in vitro also revealed
increased GJ activity and that reducing Cx43 expression
and GJ activity rescued the permeability defect in
CCM3KD cells. The focus of the current study is to define
the mechanism by which Cx43 GJs regulate permeability
and establishwhether increasedCx43 protein is a primary
defect in the maturation of CCM3 lesions in a mouse
model of fCCM3.
MATERIALS AND METHODS
Cell culture
A transformed murine brain microvascular endothelial cell line
(mBECs; Angioproteomie, Atlanta, GA, USA) was cultured in
growth media (DMEM, 4.5 g/L glucose, 13 L-glutamine, 13
antibiotic-antimycotic, 20% fetal bovine serum) at 37°C and 5%
CO2. All experiments were conducted after 24 h of serum dep-
rivation (DMEM, 4.5 g/L glucose, 13 L-glutamine).
Cell transfection
CCM1, CCM2, CCM3, andCx43 knockdownswere achieved via
transfection with Lipofectin (Thermo Fisher Scientific, Waltham,
MA, USA); 3 ccm3 small interfering RNAs (siRNAs): silencer
select s80540, s80539, s80538 (Thermo Fisher Scientific); Ccm1:
siGENOME, D-056854-02-0002; Ccm2: siGENOME, D-057315-
02-0002 (Dharmacon, Lafayette, CO, USA); and Cx43: SASI-
Mm01-00135298 (PDSIRNA2D; Sigma-Aldrich, St. Louis, MO,
USA).
Mouse model of fCCM3
C57BL/6J mice that were heterozygous for ccm3 (ccm3+/2) were
obtained from Yale University (New Haven, CT, USA) (6).
B6.129S2-Trp53tm1Tyj/J mice that carried a null mutation of
p53 (p532/2) were obtained from The Jackson Laboratory (Bar
Harbor,ME,USA).Ccm3+/2 and p532/2micewerebred together
for two generations to produce ccm3+/2p532/2 mice, which en-
abled the acquisition of a somatic second hit to ccm3 (12, 13).
MRI
All mice were anesthetized with 2% isoflurane/air mixture
throughout MRI examination. Mice lay prone, head first in a
7.0T or 9.4T Agilent MR scanner (horizontal bore; Agilent
Technologies, Palo Alto, CA, USA), with body temperature
maintained at 37°C using forced heated air. A quadrature
volume radiofrequency coil was used to scan the head region
of mice. Axial T2-weighted images were acquired by using a
fast spin-echo sequence with the following parameters:
repetition time (TR)/effective echo time (TE), 4000/60 ms;
echo spacing, 15 ms; number of echoes, 8; field of view, 203
20 mm; matrix, 2563 128; slice thickness, 0.5 mm; number of
slices, 25; and number of scans, 1 (Tscan time, 4.5 min). In
addition, T1-weighted spin-echo images were acquired pre-
and postgadolinium contrast injection by using the same
slice package as above and with a TR/TE of 600/17 ms and
an acquisition time of ;2.5 min. Finally, T2*-weighted gra-
dient echo images were acquired by using the same slice
package as above and with a TR/TE of 300/6 ms and an
acquisition time of ;2.5 min. Tracer leakage studies were
performed by intraperitoneal injection of 0.1 ml gadolinium-
diethylenetriaminepentacetate (Gd-DTPA; 0.5 mM gadoli-
nium-diethylenetriamine pentaacetic acid/ml; BioPAL,
Worchester, MA, USA). Mice were active for 10 min before
postinjection imaging.
Fusion proteins
Expression constructs used were as follows: Cx43, ZO-1, and
Claudin-5 open reading frames were cloned into pmCherry-C1
vector and pAcGFP-C1 infusion ready vector (Clontech, Moun-
tain View, CA, USA) to create N-terminally fused fluorescent
proteins. Plasmid DNA was isolated from individual trans-
formed Stellar Competent (TakaraBio, Mountain View, CA,
USA) colonies by using Qiagen plasmid midiprep kits (Qiagen,
Wetzlar, Germany). Open reading frame sequences were vali-
datedwith Sanger sequencing.mBECswere transfected byusing
TorpedoDNA (Ibidi, Fitchburg, WI, USA).
Inhibition studies
Inhibition of Cx43 GJs and HCs was achieved by cell treatment
with 100 mM GAP27 (Cx43 gap junction and hemichannel in-
hibitor) or 100 mM GAP19 (Cx43 hemichannel inhibitor; Tocris
Biosciences, Bristol, United Kingdom), respectively, for 24 h.
Treatmentdidnot affect cellviabilityas testedbyLiveDeadassay
(Thermo Fisher Scientific). To inhibit vesicular transport and
trancellular permeability, cells were pretreated with 0.1 mM
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N-ethylmaleimide (Sigma-Aldrich) for 1 h andduring the in vitro
permeability assay.
Histology and immunofluorescence
Hematoxylin and eosin and Prussian blue staining was per-
formed with frozen brain sections using standard procedures.
Lesion stage classification was performed according to criteria
described previously (5). In brief, stage 1 lesions are singular,
dilated caverns that exhibit hemorrhage. Stage 2 lesions have
segmented caverns with robust, prolonged hemorrhage. We in-
troduce stage 0 lesions as dilated vessels with little or no
hemorrhage.
Immunofluorescence staining of brain slices or cells was
performedasdescribedpreviously (4). PrimaryAbsusedwere as
follows: Cx43 (Cell Signaling Technology, Danvers, MA, USA);
ZO-1–Alexa Fluor 594, Claudin-5 unconjugated or Claudin-5–
Alexa Fluor 488 (ThermoFisher Scientific); andCD31/PECAM-1
(Novus Biologicals, Littleton, CO, USA). Secondary Abs used
were as follows: FITC anti-rabbit and Texas Red anti-mouse
(Vector Laboratories, Burlingame, CA, USA). Images were ac-
quired on the Nikon A-1 confocal microscope (Nikon, Tokyo,
Japan).
Quantitation of plaque size and TJ-associated fragments for
Cx43, ZO-1, and Claudin-5 were performed using ImageJ soft-
ware (National Institutes of Health, Bethesda, MD, USA). Three
image fields per group with equal cell number were analyzed.
Cx43 expression in the capillaries of control (ccm3+/2p53+/2)
mice or lesionsof fCCM3micewas quantified in ImageJ software
by measuring fluorescence intensity of the entire endothelial re-
gion that surrounds the control vessel or lesion. Background
fluorescence was subtracted from both control vessel and lesion
fluorescence readings. Individual lesions (10 lesions) for stage
0 and 1, 2 individual stage 2 lesions, and 10 control vessels were
analyzed from 3 control and 3 fCCM3 mice.
Super-resolution imaging
Super-resolution imagingwas conducted in conjunctionwith the
SingleMoleculeAnalysis inReal-TimeCenter at theUniversityof
Michigan (AnnArbor,MI,USA). Cellswere plated at confluency
inLabTek IICoverglass slides (0.17mmthickness; ThermoFisher
Scientific). The following primary and secondaryAbswereused:
Cx43, Claudin-5, ZO-1–Alexa Fluor 647, goat anti-rabbit IgG
Alexa Fluor Plus 647, and goat anti-mouse IgG Alexa Fluor Plus
647 (Thermo Fisher Scientific). Immediately before imaging,
sample buffer was exchanged with STORM imaging buffer
(100mMTris-Cl, 25mMNaCl, 1%v/v 2-ME, pH9.0) and freshly
added 2.5 mM PCA (3,4-dihydroxybenzoic acid; P5630; Sigma-
Aldrich) and 25 nM PCD (protocatechuate dioxygenase; P8279;
Sigma-Aldrich). Images were collected in highly inclined lami-
nated optical sheet microscopy illumination with 641-nm laser
excitation on an Olympus IX81 microscope with a cell^TIRF
module (Olympus, Tokyo, Japan). Images were collected on an
Andor iXon Ultra EMCCD camera. Images were processed by
using the ThunderSTORM plugin of ImageJ.
Quantitative PCR
Qunatitative PCR was performed after Trizol/chloroform RNA
extraction and reverse transcription (SuperScript II RT; Thermo
Fisher Scientific). Reactions were performed with SYBR Green
PCR Master Mix and analyzed with 7500 Real-Time PCR Sys-
tem (Applied Biosystems, Foster City, CA, USA). Primers used
were as follows: Cx37: forward: 59-CTGGACCATGGAGCCGGTGT-
39, reverse: 59-GGTTGAGCACCAGGGAGATGACTC-39; Cx40:
forward: 59-TCCAGGGCACCCTACTCAACACCT-39, reverse: 59-
GGACTCCTGCGGCAGACATGC; Cx43-39: forward: 59-TAC-
CACGCCACCACCGGCCCA-39, reverse: 59-GGCATTTTGGCT-
GTCGTCAGGGAA-39; and b-actin: forward: 59-GCCCTGAGGC-
TCTTTTCCAG-39, reverse: 59-TGCCACAGGATTCCATACCC-39
(n = 3 per group, normalized to b-actin expression). DDCt values
were calculated, and fold-change reported.
Western blotting
Primary Abs used were as follows: Cx37 (Abcam, Cambridge,
MA, USA); Cx40 (GeneTex, Irvine, CA, USA); Cx43 and b--
tubulin; CCM1 (Boster Bio, Pleasanton, CA, USA); CCM2
(Sigma-Aldrich); CCM3 (ProteinTech, Rosemont, IL, USA); and
ZO-1 and Claudin-5 (Thermo Fisher Scientific). Reactions were
visualized with the following secondary Abs: goat anti-rabbit
IgG-horseradish peroxidase conjugate or goat anti-mouse IgG-
horseradishperoxidase conjugate (Bio-Rad,Hercules, CA,USA).
Blots were developed with SuperSignal West Femto Maximum
SensitivitySubstrate (ThermoFisherScientific) and imagedusing
the Molecular Imager ChemiDoc XRS+ Imaging System (Bio-
Rad). Band intensities were analyzed by using Image Lab soft-
ware (Bio-Rad).
GJ activity assays
Scratch assay was performed as follows: cells were grown to
confluency before siRNA treatment. After media removal, the
cell monolayer was disrupted with a single scratch. Lucifer yel-
low (LY; 0.05%; Sigma-Aldrich) was immediately applied to the
scratch for 30 s. Cells were subsequently washedwith PBS, fixed
with 4%paraformaldehyde for10min, then immediately imaged
by using a 488-nm laser line. Cell confluency that surrounded the
scratch was confirmed under transmitted light. LY transfer dis-
tancewasmeasured perpendicularly from scratch to the furthest
LY+ cell using ImageJ. Three independent scratches with 10 dis-
tance measurements per scratch were analyzed per group.
Microinjections were performed by using the PicoSpritzer 3
(ParkerHannifin, Richland,MI, USA). Cellswere grown on Ibidi
35-mm low, grid 500, ibiTreat plates. Cell-of-origin grid location
was recorded. Eppendorf Femptotips Microinjection capillary
tips (0.5 mm; Thermo Fisher Scientific) were loaded with 0.05%
LY. Healthy, confluent cells were injected at 40 kPa for 500 ms.
LY injection was visualized in real time to ensure LY injection
into the cell of origin. Three injections were performed at dis-
tant spots on each plate. After injection, cells were washed in
PBS, fixed using 4% paraformaldehyde, and imaged immedi-
ately. LY+ cells that surrounded the cell of origin were counted
by using ImageJ.
Fluorescence resonance energy transfer
and fluorescence recovery after
photobleaching analysis
Fluorescence resonance energy transfer (FRET) and fluorescence
recovery after photobleaching (FRAP) experiments were per-
formed by using a Leica SP5X inverted 2-photon FLIM confocal
microscopewithLASXsoftware (Leica,Mannheim,Germany) at
the University of Michigan Microscopy Imaging Laboratories.
Laser power and line intensities used were as follows: FRET:
white light laser, 70%; red laser line, 587 nm; 40% intensity; green
laser line, 488 nm; 30% intensity; acceptor photobleaching per-
formed with laser lines at 579, 587, and 595 nm at 100% for 80 s;
FRAP: argon laser, 25%; green laser line, 488 nm; 30% intensity;
photobleaching performed with 488 nm at 100%. Laser power
and laser line intensities were kept constant across samples.
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Experimental valueswere calculatedas follows: FRETefficiency=
[(donorpost2donorpre)/donorpost]; FRAP,%recovery= [(6min
postbleach fluorescence 2 0 min post bleach fluorescence)/
prebleach fluorescence] 3 100.
Background controls used for FRET and FRAP experiments
were as follows: FRET: background efficiency = FRET efficiency
of coexpressed empty AcGFP and mCherry vectors subtracted
from experimental FRET efficiencies during analysis; FRAP: a
background region of interest (ROI) was selected in non-GFP+
region. Background ROI percent recovery was subtracted from
the experimental ROIs analyzed.
Transendothelial electrical resistance assay
Cells were grown to confluency in 12-mm Transwells with
0.4-mm pores (Corning, Corning, NY, USA) before manipu-
lation. Transendothelial electrical resistance (TEER) values
weremeasured by using the EVOM2Epithelial Voltohmmeter
(World Precision Instruments, Sarasota, FL, USA). Blank
measurements—media only, no cells—were subtracted from
experimental values during analysis.
In vitro permeability assay
mBEC monolayers were established in the 12-mm Transwell
system with 0.4-mm pore size. Permeability experiments were
initiated with the addition of FITC-inulin (Sigma-Aldrich) to the
apical (donor) chamber.Thepermeability coefficient (centimeters
per minute) of the monolayer during any time interval (T) was
calculated as follows:
PC ¼ ½CðBÞT2CðBÞ×VðBÞ×2½CðAÞ þ CðAÞT×A×T
;
where C(B) and C(B)T are the concentrations (nanograms per
milliliter) of FITC-inulin in the basal (receiving) chamber at the
start and at the end of the time interval, respectively, andV(B) is
the volume of the basal chamber (in milliliters). C(A) and C(A)T
are the concentrations of FITC-inulin in the apical (donor)
chamber at the start and at the end of the time interval, re-
spectively, and [C(A) + C(A)T]/2 is the average concentration
over the time interval. T is the duration of the time interval (in
minutes), whereas A is the area of the filter (square centimeters).
All samples were read on a fluorescent reader (Infinity FL200;
Tecam, Saint Charles, IL, USA). The concentration of FITC-inulin
in samples was calculated from a standard curve that was de-
rived using known concentrations of tracer (4, 14, 15).
For transcellular permeability, the percentage of cellular up-
take of FITC-albumin was evaluated at 37°C by adding FITC-
albumin (1 mg/ml) and in the presence or absence of unlabeled
albumin. Uptake at 37°Cwas allowed to proceed for time points
0–120 min (15-min interval), then terminated by chilling on ice
and washing 3 times with PBS buffer. Cell-surface binding of
FITC-albumin was removed by 0.5 ml acid buffer (0.5 M NaCl
and 0.2 M acetic acid, pH 2.5). Cells were lysed with 0.5 ml of
50mMTrisHCl, pH7.4, that contained1%TritonX-100and0.5%
SDS, and the sample was read on a fluorescent reader (15).
Statistical analyses
Statistical analyses were performed by using Prism 6.0 (Graph-
Pad Software, La Jolla, CA, USA). Data in bar graphs represent
means6 SEM. In experiments that compared 2 groups, significant
differences were determined by unpaired, 2-tailed Student’s t
test. In experiments that compared .2 groups, significant dif-
ferenceswere determined by a 1-wayANOVAwith Tukey’s post
hoc test. A probability value of P, 0.05 was considered statisti-
cally significant.
RESULTS
GJ protein, Cx43, is elevated in an fCCM3
mouse model
To study the role of Cx43 in fCCM3, we bred a mouse
model of fCCM3 [ccm3+/2p532/2 mice, described pre-
viously (6)] on the basis of the 2-hit hypothesis of fCCM in
which a second somatic mutation is acquired in the func-
tional allele of heterozygous patients (12). fCCM mouse
models on p532/2 backgrounds develop cerebrovascular
hemorrhagic lesions. Additional organ pathologies were
not detected (6). ccm3+/2p532/2 mice were evaluated for
the presence of hemorrhagic cerebrovascular lesions that
were consistent with human disease by using T2*-
weightedMRI imaging. Several hemorrhagic lesionswere
present in multiple regions of the brain at age 5 wk (Fig.
1A). Lesion volume varied between 0.005 and 1.0 mm3.
New hemorrhagic lesions appeared at a rate of 3–4.5 le-
sions per week (data not shown).
Given that BBB hyperpermeability is the central path-
ologic feature of fCCM3, lesion permeability in the
ccm3+/2p532/2model was evaluated by usingGd-DTPA
injection. Gd-DTPA leakage could frequently be ob-
served in conjunction with hemorrhage on companion
T2*-weighted MRI images. Lesions were categorized
into 2 types: permeable (Gd-DTPA leakage only, non-
hemorrhagic) and hemorrhagic (Fig. 1B). When first
assessed at age 9 wk, ccm3+/2p532/2 mice had roughly
equivalent numbers of permeable and hemorrhagic le-
sions. Hemorrhagic lesions were most prevalent by age
13 wk (Fig. 1B). When individual permeable lesions at
age 9 wk were followed to age 13 wk, the probability of
lesion hemorrhage was 100% (data not shown). These
findings demonstrate that developing lesions have
compromised BBB function before hemorrhage. Of im-
portance, lesion permeability predicts hemorrhage.
Histologic examination of lesion maturation in hema-
toxylin and eosin–stained sections revealed stage 0, 1,
and 2 lesions, classified as described in Materials and
Methods (Fig. 1C, D). Evaluation of prolonged hemor-
rhage by iron accumulation using Prussian blue staining
revealed iron accumulation in stage 1 and 2 lesions.
Overall, lesion maturation progresses from a permeable
dilatedvessel (stage 0) to reorganized, cystic-like caverns
with a complete loss of barrier properties and hemor-
rhage (stages 1 and 2).
We sought to identify proteins that are aberrantly
expressed in stage 0 lesions that promote BBB hyper-
permeability and enable lesion maturation. Aberrant ele-
vation of Cx43 protein has recently been linked to
increased barrier permeability (10, 11). Immunofluores-
cence staining of Cx43 in ccm3+/2p532/2 lesions revealed
dramatically increasedCx43expression inall lesion stages,
particularly at stage 0, which correlates with lesion pro-
gression (Pearson coefficient r = 0.7074; P , 0.01; Fig. 1C,
D). The increased expression of Cx43 was observed in
2618 Vol. 32 May 2018 JOHNSON ET AL.The FASEB Journal x www.fasebj.org
Figure 1. Developing lesions expressing Cx43 are susceptible to hemorrhage. A) T2* MRI images of a ccm3+/2p532/2 mouse and
ccm3+/2p53+/2 control mouse. Multiple hemorrhages of variable size are visible in the ccm3+/2p532/2 mouse (black arrows).
Compiled lesion volumes of 3 ccm3+/2p532/2 mice assessed at age 5, 8, 9, 11, and 13 wk. B) Representative image of ccm3+/2p532/2
mouse lesions with Gd-DTPA leakage only (top) and Gd-DTPA + hemorrhage (bottom) as assessed by T1-weighted (Gd-DTPA)
or T2*-weighted (hemorrhage) imaging. The number of Gd-DTPA+ lesions with or without hemorrhage was counted at age 9, 11,
and 13 wk and presented as a percent of the total number lesions identified in T1 or T2* images. C) Hematoxylin and eosin
(panel 1), Prussian blue (panel 2, black arrows indicate spots of iron accumulation), and immunofluorescence staining of CD31
(panel 3), Cx43 (panel 4), merge images (panel 5), PDGFRb (panel 6), Cx43 (panel 7) and merge images (panel 8) of stage 0, 1,
and 2 lesions and control vessels in ccm3+/2p532/2 mice. Scale bar, 100 mm. D) Quantitation of Cx43 expression in control and
lesion stages (n = 10; n = 10 individual lesions for stage 0 and 1; n = 2 individual lesions for stage 2). Cx43 was quantified using
ImageJ by selecting the entire endothelial layer surrounding each lesion and measuring the fluorescent signal. Cx43 expression is
quantified relative to control vessel fluorescence. E) Comparison of Cx43 expression and lesion volume (Pearson coefficient r =
0.7074, P , 0.01). ***P , 0.0001 compared to control, **P , 0.01 compared with stage 0, ***P , 0.001 compared with stage 1.
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brain endothelial cells (CD31+) and surrounding pericytes
(platelet-derived growth factor receptor b+ cells; Fig. 1C).
Given our observation that Cx43 is significantly elevated
in permeable stage 0 lesions, Cx43 was pursued for addi-
tional study to identify its pathogenic functions in fCCM3.
Cx43 protein and GJ activity is increased by
CCM3KD in vitro
We established an in vitro fCCM3 model by using
CCM3KD in a mBEC line, achieving 85% efficiency of
CCM3KD (Supplemental Fig. 1). Cx43 protein, but not
transcript, is elevated in CCM3KD cells (Fig. 2A, B). No
difference in protein expression was observed for Cx37
and Cx40, additional Cx family members that are
expressed by brain endothelial cells, although a compen-
satory up-regulation of Cx40 transcriptwas apparent (Fig.
2A, B). To determine whether Cx43 is elevated in other
fCCM subtypes, Cx43 protein expressionwas analyzed in
CCM1KD andCCM2KD cells, which revealed significant,
but not robust, elevation compared with control cells
(Supplemental Fig. 1).
Cx43 has many functions that are dependent on its
cellular localization (16, 17). Cell fractionation analysis of
Cx43 revealed that Cx43 is localized exclusively to the in-
soluble fraction in control cells, and CCM3KD does not
change its cellular localization (Fig. 2C). Immunofluores-
cence staining of Cx43 confirmed that, in both control and
CCM3KD cells, Cx43 was localized to the membrane and
formedplaque-like structures thatwere consistentwithGJ
plaques (Fig. 2E). Quantitation of Cx43 GJ plaque size
revealed significantly increased Cx43 GJ plaque size in
CCM3KD cells compared with controls (Fig. 2F). FRAP
analysis suggested that no difference in Cx43 mobility
within GJ plaques exists between control and CCM3KD
cells (Fig. 2D).
We evaluated whether enlarged Cx43 GJ plaques in
CCM3KD cells have a functional effect on GJ intracellular
communication (GJIC). Single-cell microinjection of LY, a
noncell permeable dye, into control or CCM3KD cell
monolayers demonstrated a significantly higher capacity
for CCM3KD cells to transfer dye to adjacent cells than
control cells (Fig. 3A). Scratch assay analysis of LY transfer
in control or CCM3KD cellmonolayers also demonstrated
significantly elevated GJIC in CCM3KD cells compared
with controls. To validate that LY transfer occurred spe-
cifically via Cx43 GJs, and not Cx37 or Cx40 GJs, we per-
formed scratch assays in the presence of aCx43GJ-specific
peptide inhibitor, GAP27 (18). GAP27 completely inhibi-
ted CCM3KD GJIC, which indicated that Cx37 and Cx40
were not directly contributing to GJIC in CCM3KD cells.
Morphologic analysis suggested that prolonged GAP27
treatment inhibited GJIC by decreasing GJ plaque size in
CCM3KD cells (Fig. 3B). Super-resolution imaging high-
lighted the reduction in GJ plaque size (Fig. 3C).
Cx43 expression in ccm3+/2p532/2 lesions suggests that
elevatedCx43 is associatedwithpermeability. To evaluate
whether elevated Cx43 protein expression in CCM3KD
cells contributes to hyperpermeability that is characteris-
tic of fCCM3, we measured TEER and permeability
(clearance) for tracer inulin in CCM3KD cells in which
Cx43protein expressionwas reduced via siRNA-mediated
knockdown (Fig. 4A, B and Supplemental Fig. 2A). As
expected, CCM3KD cells exhibited highly permeable
monolayers, as did wild-type cells that overexpressed
Cx43 (Cx43over).Of importance, reducingCx43 expression
in CCM3KD cells partially, but significantly, restored the
integrity of CCM3KDmonolayers (Fig. 4B).
To test which function of Cx43 is pathologic to perme-
ability, we examined whether the inhibition of Cx43 GJIC
could rescue CCM3KDmonolayer permeability (Fig. 4C).
TEER analysis of control and CCM3KD cells in the pres-
ence of GAP27 or GAP19, a Cx43 HC-specific inhibitor
(19), revealed that GAP27 completely rescued CCM3KD
monolayer permeability, with no adverse effect on control
cells, whereas GAP19 had no effect on CCM3KD TEER.
This Cx43 effect on brain endothelial monolayer perme-
abilitywasaccomplishedmostlybyopeningaparacellular
route, whereas transcellular permeability, measured by
transcellular transport of FITC-albumin, was affected to a
modest degree (Fig. 4D).
Analysis of key occlusion (Claudin-5) and scaffolding
(ZO-1)proteins indicated thatCCM3KDandCx43over cells
exhibited reduced expression of both Claudin-5 and ZO-1
(Fig. 5A), which suggested that elevated Cx43 protein ex-
pression may be pathologic to CCM3KD cells by regulat-
ing permeability with a TJ protein expression–dependent
mechanism. As in CCM3KD and Cx43over cells, CCM3
lesions unveiled the same pattern of Claudin-5 and ZO-1
expression. Both TJ proteins demonstrated decreased ex-
pression in CCM3 lesions and negatively correlated
with increased lesions (Claudin-5: r=20.8621; ZO-1; r=
20.8331) and increased Cx43 expression (Claudin-5: r =
20.726; ZO-1: r = 20.6201; Fig. 5B, C).
Cx43 GJs disrupt TJ formation in CCM3KD cells
Having determined that Cx43 GJIC is pathologic to
CCM3KD permeability, we next examined how Cx43 GJs
regulate permeability in CCM3KD cells. ZO-1 emerged as
a candidate protein that links Cx43 to permeability be-
cause of a well-described Cx43–ZO-1 interaction (20). The
Cx43–ZO-1 interaction restricts Cx43 GJ size (21–23);
however, whether Cx43 GJs can regulate ZO-1, particu-
larly its function in TJs, is unknown. We tested the hy-
pothesis that Cx43 GJs affect the organization of TJs via
regulating ZO-1 localization. Immunofluorescence analy-
sis of Cx43 and ZO-1 colocalization in control, CCM3KD,
and GAP27-treated CCM3KD cells revealed significant
differences in the TJ association (continuous cell border
staining) andGJ association (Cx43–ZO-1 colocalization) of
ZO-1 (Fig. 6A). ZO-1 in control cells exhibits preferential
localization to TJs and low accumulation at GJs. In con-
trast, ZO-1 in CCM3KD cells exhibited fragmented local-
ization toTJs andaberrant accumulationatGJs (Fig. 6B,C).
Comb-like ZO-1 structures that extend into the cytosol
from the cell border, characteristic of disorganized ZO-1,
were observed in super-resolution imaging of ZO-1 in
CCM3KD cells (Fig. 6D). Of interest, inhibition of Cx43
GJIC in CCM3KD cells with GAP27 partially restored the
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localization of ZO-1 to TJs and prevented the accumula-
tion at GJs.
We analyzed the mobility of TJ-associated ZO-1 with
FRAP (Fig. 6E). Given its size and function as a scaffolding
protein, ZO-1 is a relatively immobile protein in healthy
cells. We determined that ZO-1 is significantly more mo-
bile in CCM3KD cells compared with controls, which
supports our finding thatZO-1 is not sufficiently anchored
Figure 2. Cx43 protein is increased in CCM3KD brain endothelial cells. A) Control or CCM3KD (siRNA-mediated 85% CCM3
knockdown; Supplemental Fig. 1) whole-cell lysates were prepared and analyzed via Western blot. Cx43 protein, but not Cx37 or
Cx40 protein, is significantly elevated relative to control (n = 3 independent experiments). *P , 0.05 compared to control. B)
RNA extracted from control and CCM3KD cells and subjected to reverse-transcription quantitative PCR revealed no significant
changes in Cx43 transcript. Data represent means 6 SEM fold-change normalized to b-actin (Cx43: n = 6, Cx40, Cx37: n = 3
independent experiments). **P , 0.01 compared with control. C) Whole-cell lysates were subjected to cell fractionation. Cx43
was only present in the insoluble fraction (caveolin-1) and not in the cytosol (Hsp70; representative Western blot, n = 3
independent experiments). D) FRAP analysis of control and CCM3KD cells expressing Cx43-AcGFP. FRAP was performed on
membrane ROIs (n = 6 ROIs from 6 cells). E) Immunofluorescence staining of Cx43 (column 1), merged Cx43, and DAPI
staining (column 2), and zoom images of Cx43 GJs along the cell membrane (column 3, dashed lines) in control and CCM3KD
cells (GJ plaques are indicated with white arrows). Scale bar, 100 mm. F) Cx43 GJ plaque size was measured in ImageJ. For 3
image fields with ;8 cells/field, the entire membrane region of every cell was selected to analyze particle (GJ plaque) size in
Cx43-labeled samples. Average plaque size is reported as mean 6 SEM of all GJ plaques measured (;50 plaques/field). This
analysis revealed significantly larger GJ plaques in CCM3KD cells compared with controls. **P , 0.01.
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in TJ structures. GAP27 treatment restores ZO-1 mobility
to control levels, which is also consistent with the re-
distribution of ZO-1 to TJ structures in GAP27-treated
CCM3KD cells.
To further delineate the nature of Cx43–ZO-1 colocali-
zation that was observed in CCM3KD cells, we used
acceptor-photobleaching FRET analysis in cells that coex-
pressed Cx43-mCherry and ZO-1–AcGFP. FRET effi-
ciency between Cx43 and ZO-1 in CCM3KD cells was
significantly lower compared with controls (Fig. 6F),
which indicated that whereas Cx43 and ZO-1 strongly
colocalize in CCM3KD cells, they do not physically
interact to the same extent as in control cells. This is con-
sistent with our data that indicate higher GJ activity and
the literature that shows that Cx43–ZO-1 interaction in-
hibits GJIC. Finally, GAP27 treatment of CCM3KD cells
restores the Cx43–ZO-1 interaction, which is consistent
with the inhibition ofGJIC and further supports the notion
that the Cx43–ZO-1 interaction is important for Cx43-
mediated effects on permeability.
We extended our analysis of Cx43 GJ-mediated regu-
lation of TJs to include the TJ transmembrane protein,
Claudin-5. Similar to ZO-1, we observed that Claudin-5 is
more mobile in CCM3KD cells compared with controls.
Figure 3. CCM3KD cells have increased GJIC. A) GJIC measured by microinjection (top) and scratch assay (bottom). Single-cell
injections were performed in control and CCM3KD samples. The number of neighboring LY+ cells was counted in ImageJ (n = 3
independent injections over 3 plates). *P , 0.05. Scratch assays also revealed a significant increase in GJIC function as measured
by the distance of LY spreading perpendicular to the scratch (black arrows below image) in CCM3KD cells compared with
controls. GJIC could be rescued by treatment with 100 mmGAP27 for 24 h. Magnification,34. Data represent means6 SEM (n = 3
independent experiments, 10 measurements/experiment). ***P , 0.0001 compared with control or CCM3KD. B)
Immunofluorescence staining of Cx43 GJ plaques (white arrows) in control, CCM3KD, and CCM3KD + GAP27 reveals the
rescue of plaque size by 100 mM GAP27 treatment for 24 h. Scale bar, 100 mm. Plaque size was quantified in ImageJ as described
in Fig. 2F (n = 3 image fields, ;50 plaques/field). **P , 0.01 compared with control. C) Super-resolution imaging of control,
CCM3KD, and CCM3KD cells treated with 100 mM GAP27 for 24 h. Arrows indicate cell border, stars indicate GJ plaques.
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This trend was rescued by GAP27 treatment (Fig. 7A).
Super-resolution imaging of Claudin-5 demonstrated
continuous staining of Claudin-5 along the cell border in
control cells,whichwas indicative ofTJ incorporation (Fig.
7B). As with ZO-1, TJ-incorporated Claudin-5 seems to be
fragmented in CCM3KD cells, but GAP27-mediated in-
hibition of Cx43GJIC restored the localization of Claudin-
5 to TJs. Examination of ZO-1–Claudin-5 colocalization, a
necessary step for the formation of functional TJs (23), in-
dicated expected colocalization at TJ structures along the
cell border in control cells, but fragmented TJ-associated
Claudin-5 in CCM3KD cells (Fig. 6C). Quantitation of TJ-
associated Claudin-5 fragment length revealed highly
fragmentedTJ-associatedClaudin-5 inCCM3KDcells, but
rescued TJ-associated fragment length by inhibition of
Cx43 GJIC with GAP27. Finally, we analyzed the fre-
quency of Claudin-5–ZO-1 and Claudin-5–Claudin-5
transinteractions with FRET (Fig. 7D, E). TJ-associated
Claudin-5 and ZO-1 interacted less frequently in
CCM3KD cells, but this interaction was restored by
Cx43 GJIC inhibition. Similarly, Claudin-5–Claudin-5
transinteraction was compromised in CCM3KD cells, but
restored by the GAP27-mediated inhibition of Cx43 GJIC.
DISCUSSION
Hyperpermeability is theprimarydefect of fCCM3 lesions;
however, the underlying mechanism that contributes to
hyperpermeability is not well defined. The present study
observed that 1)Cx43 forms largeGJ plaques anddisplays
increasedGJIC in CCM3KD cells; 2) the inhibition of Cx43
GJIC completely rescued CCM3KD hyperpermeability; 3)
Cx43GJs regulatedpermeabilityviamodulatingTJprotein
localization; and 4) Cx43 protein expression in lesions of
ccm3+/2p532/2mice was elevated.
Permeability of the brain microvascular system is reg-
ulated, in part, by the TJ complex. The formation of TJ
structures on the membrane is a highly regulated, multi-
step process. ZO-1 is recruited and distributed along the
cell border, which signals the recruitment and insertion of
claudins and occludin into the membrane, which in turn,
Figure 4. Depletion of Cx43 protein and GAP27-mediated inhibition of Cx43 GJIC rescues CCM3KD monolayer permeability. A)
Transwell TEER assays revealed a significant increase in CCM3KD permeability and partial, significant rescue after the reduction
of Cx43 expression in CCM3KD cells via Cx43 siRNA-mediated KD. Data represent means 6 SEM (n = 3–10 independent
experiments). *P , 0.05, ***P , 0.0001 compared with control, ***P , 0.001 compared with CCM3KD. Cx43 + CCM3KD
efficiency is reported in Supplemental Fig. 2. B) Permeability coefficient (PC) of inulin (MW = 5 kDa) shows increased
permeability of CCM3KD and Cx43over mBEC monolayers, whereas the depletion of Cx43 via siRNA rescued mBEC monolayer
integrity. Data represent means 6 SEM. ***P , 0.001 compared with control, ***P , 0.001 compared with CCM3KD. C)
Transwell TEER assays performed with control and CCM3KD cells treated with 100 mm GAP19 or 100 mM GAP27 for 24 h.
Treatment with GAP27 completely rescued CCM3KD permeability. GAP19 treatment had no effect (n = 3–10 independent
experiments). ***P , 0.0001 compared with control or CCM3KD. D) Transendothelial albumin permeability was only slightly
increased in CCM3KD and Cx43over monolayers compared with control. Inhibition of vesicular transport with N-ethylmaleimide
(NEM) did not disturb the albumin monolayer permeability, which indicated that CCM3 and Cx43 predominantly regulate
paracellular permeability. Data represent means 6 SEM. *P , 0.05 compared with control.
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allows transinteractionsbetweenclaudinsandoccludinon
neighboring cells (23). Claudin-5 is a particularly crucial
claudin for BBB occlusion. Claudin-5 knockout mice die
hours after birth from brain edema as a result of inhibited
BBB occlusion (24). Other claudin KO mice suggest that
Claudin-5 is uniquely important for barrier occlusion (25).
Previous works have demonstrated that fCCM3 lesions
have highly disorganized TJ structures, including absent
or incomplete incorporation of ZO-1 and Claudin-5 into
TJs, and suggest that this is a principal mechanism by
which fCCM3 lesions are hyperpermeable (4); however,
the underlying mechanism that contributes to TJ organi-
zation has not been defined.
Elevated Cx43 has recently been suggested to be detri-
mental to barrier permeability in GJ- and HC-dependent
mechanisms. Multiple studies in lung endothelia have
Figure 5. A) Representative Western blot and quantification of Cx43, Claudin-5, and ZO-1 in whole-cell lysates of control,
CCM3KD, and Cx43 overexpressing (Cx43over) cells (n = 3 independent experiments). Cx43: *P , 0.05, **P , 0.01 compared
with control; ZO1: *P , 0.05, **P , 0.01 compared with control; Claudin-5: *P , 0.05 compared with control. B, C)
Immunofluorescence staining for Claudin-5 (B) and ZO-1 (C) in control and CCM3 lesion stage 1 unveiled decreased Claudin-5
expression. Correlation between Claudin-5/ZO-1 expression and lesion volume (Pearson coefficient: Claudin-5: r = 20.8621;
***P , 0.001; and ZO-1: r = 20.8336, ***P , 0.001) and Claudin-5/ZO-1 and Cx43 expression in CCM3 lesion (claudin-5: r =
20.726 ***P , 0.001; and ZO-1: r = 20.601, ***P , 0.001). Scale bar, 100 mm.
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demonstrated the rescue of barrier properties after sup-
pression of inflammation-induced Cx43 expression (11,
26). In brain endothelia, elevated GJIC is suggested to be
pathogenic tobarrier functionbecauseof the effectsofCa2+
propagation on cytoskeletal integrity or localized endo-
thelial cell death (27, 28). Cx43 has not previously been
evaluated in fCCM. We observed robust expression of
Cx43 in all stages of lesions in ccm3+/2p532/2 mice, with
particularly high expression in developing stage 0 lesions.
Brain endothelial cells that were subjected to CCM3KD
also demonstrated high protein expression of Cx43 and
formed abnormally large GJ plaques that resulted in
Figure 6. Inhibition of Cx43 GJIC rescues TJ disorganization in CCM3KD cells. A) Immunofluorescence staining of Cx43 and ZO-
1 in control, CCM3KD, and CCM3KD + GAP27 (100 mm) cells. Zoom images demonstrate Cx43 GJ-plaque associated ZO-1 and
TJ-associated ZO-1, represented by continuous staining along the cell border. Scale bar, 100 mm. B) Quantitation of Cx43 GJ-
associated ZO-1 plaque size was performed in ImageJ by measuring individual ZO-1 plaques associated with Cx43 as determined
by corresponding Cx43–ZO-1 merged images. Three image fields with ;8 cells/field, 15 plaques/field were analyzed. CCM3KD
cells display significantly larger Cx43-associated ZO-1 plaques compared with control. GAP27 treatment of CCM3KD cells
significantly reduced CCM3KD ZO-1 plaques. ***P , 0.0001, **P , 0.01 compared with control, **P , 0.01 compared with
CCM3KD. C) Quantitation of TJ-associated ZO-1 fragments along the cell border. The length of ZO-1 fragments along the cell
border was measured for 3 image fields with 8 cells/field in ImageJ. ***P , 0.0001, **P , 0.01 compared to control, ***P ,
0.0001 compared with CCM3KD. D) Super-resolution images of TJ-associated ZO-1 fragments on the cell border (arrows) and
comb-like organization in CCM3KD cells (star). E ) FRAP analysis of TJ-associated ZO-1 in control, CCM3KD, and
CCM3KD+GAP27 cells expressing ZO-1-AcGFP. *P , 0.05 compared with control. F) Acceptor photobleaching FRET of Cx43
GJ-associated ZO-1 in cells coexpressing Cx43-mCherry and ZO-1-AcGFP in control, CCM3KD, or CCM3KD + GAP27 cells (n = 30
ROIs/group). *P , 0.05 compared with control.
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elevated GJIC. We found that reducing Cx43 expression
and specific blockage of GJIC, but not HC function, res-
cued their hyperpermeability.
Understanding how elevated GJIC in fCCM3 causes
hyperpermeability is of great importance. Here, we
propose a mechanism that is separate from the afore-
mentioned studies that examined Cx43-dependent
hyperpermeability by which increased Cx43 GJs inhibit
the distribution of ZO-1 and, consequently, Claudin-5 to
the TJ. A large body of literature has described the in-
teraction betweenCx43 andZO-1 in the context ofGJ size
and activity, in which the direct interaction of Cx43 and
ZO-1 at theGJ plaque perimeter decreasesGJ plaque size
and activity (29, 30).We observed a phenomenon not yet
described by which ZO-1 accumulates at the GJ plaque
perimeter in CCM3KD cells, but does not physically in-
teract, as determinedbyFRET analysis. It is unclearwhat
mechanism in CCM3KD cells signals the preferential
localization and accumulation of ZO-1 at Cx43 GJs over
TJ localization. Changes in the accessibility of regulatory
sites on Cx43 in its active state in CCM3KD cells may
prevent ZO-1 trafficking within the membrane and the
subsequent Claudin-5 recruitment (31). When GJ pla-
ques are disbandedbyGAP27 treatment, the preferential
Figure 7. Claudin-5 incorporation into TJs is rescued by Cx43 GJ inhibition. A) FRAP analysis of Claudin-5 (Cldn5) in control,
CCM3KD, and CCM3KD + GAP27 (100 mm) cells expressing Claudin-5–AcGFP. B) Super-resolution imaging of TJ-associated
Claudin-5 (arrows). C) Immunofluorescence staining of Claudin-5 and ZO-1 in control, CCM3KD, and CCM3KD + GAP27 (100
mM) cells. Scale bar, 25 mm. D) Quantitation of the average TJ-associated Claudin-5 fragment length in Claudin-5/ZO-1 costained
immunofluorescent images. Fragment length was measured in ImageJ as described for ZO-1 fragment length in Fig. 5C. *P ,
0.05, ***P, 0.0001 compared with control, ***P, 0.0001 compared with CCM3KD. E) FRET analysis of TJ-associated Claudin-5
and ZO-1 in cells coexpressing Claudin-5–mCherry and ZO-1–AcGFP. The number of cell-border ROIs giving a FRET signal
(FRET+ ROI) was measured as a percent of the total number of cell-border ROIs analyzed [n = 20 total ROIs (4 ROIs/cell), 2
independent experiments]. F) FRET analysis of Claudin-5 transinteraction. Cells were separately transfected with either Claudin-
5–AcGFP or Claudin-5–mCherry at 1:1 concentration, then seeded together. ROIs in which neighboring cells exhibited
incorporation of Claudin-5–AcGFP and Claudin-5–mCherry into a shared TJ were selected for FRET analysis. FRET was
performed and analyzed as described in Fig. 6E for 15 ROIs (3 ROIs/cell) and 2 independent experiments.
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conditions switch such that ZO-1 localizes to TJs and
does not accumulate at Cx43 GJs. Consequently,
Claudin-5 is also relocalized at the TJ and forms trans-
interactionswith neighboring cell Claudin-5,which seals
the barrier.
Consequences in addition to GJIC-induced hyper-
permeability should be considered in the pathology of
fCCM3. In particular, elevated GJIC may represent a
mechanism by which injury can be propagated to
otherwise healthy cells, including other cell types of
the neurovascular unit, pericytes and astrocytes. Sev-
eral fCCM studies have demonstrated disrupted neu-
rovascular unit architecture in which pericytes and
astrocytes lose contact with endothelial cells or are
completely absent (29, 30, 32–34). It is also important to
highlight that fCCM3 lesions are believed to be initi-
ated by a second hit to the functional ccm3 allele (12,
13); however, it is not clear when in development this
second hit is acquired or how many ccm32/2 cells are
required to initiate a lesion. Whereas endothelial
cell–specific ccm3KO mice develop fCCM3, and as-
trocyte- and neuron-specific ccm3KO mice show low
or no fCCM disease penetrance, respectively, it is not
yet understood whether multiple cell types are in-
volved in the initiation and maturation of lesions (6,
35). Elevated GJIC in ccm32/2 cells may represent a
mechanism by which ccm3+/2 cells become damaged,
despite being genetically healthy.
Of note, Cx43 is the only Cx family member that is
expressed in brain endothelial cells that is affected at the
protein level byCCM3KD. Several subtle, but functionally
significant, differences exist between Cx family members,
particularly with the existence of phosphorylation sites at
the C-terminal tail that direct the Cx cycle, interactome,
and downstream signaling events in response to stimuli
(36). Given the accumulation of Cx43 protein without up-
regulation of Cx43 transcript, it is possible that sites at the
C-terminal tail thatdirectCx43degradationorendocytosis
are affected by CCM3KD and result in accumulation at
the membrane. ZO-1 accumulation at Cx43 GJ plaques
occurs directly before the invagination of GJ plaques
from the plasma membrane, representing a possible
link between our observations of reduced ZO-1 in-
teraction with Cx43 and Cx43 GJ plaque accumulation
(29). Future work should focus on delineating the
mechanism by which CCM3 regulates Cx43 specifi-
cally and, in addition, whether Cx43 is unique among
the Cxs in its ability to regulate the establishment
of TJs.
We have demonstrated that Cx43 is most robustly af-
fected by CCM3KD and less so by CCM1 or CCM2KD.
Proteomic analysis of the CCM3 interactome has revealed
that 80% of total CCM3 protein is bound to the STRIPAK
complex and 20% is bound to a CCM1-CCM2-CCM3
complex; thus, the STRIPAK complex is likely responsible
for downstream events that are unique to CCM3 (2, 37).
Given that the most robust effect of CCMKD on Cx43
protein occurs via the loss of CCM3, it is possible that the
CCM1andCCM2effects onCx43 are propagated through
CCM3 via the CCM1-CCM2-CCM3 complex. The STRI-
PAK complex has many functions in the cell, regulating
several phosphatases and kinases, and CCM3 is capable
of regulating the activation of GCKIII kinases within
the STRIPAK complex (3, 4). Elucidation of a CCM3-
STRIPAK-Cx43 regulatory axis is needed. Several resi-
dent STRIPAK proteins are likely candidates, including
calmodulin andPP2A. The former acts as a calcium sensor
and regulates Cx43 channel opening, whereas the latter
directly dephosphorylates residues Ser279/Ser282 of
Cx43, which inhibits Cx43 GJ plaque formation (38–40).
Elevated ERK1/2 activation is a consequence of
CCM3 loss from the STRIPAK complex and causes
the dysregulation of TJ structure via modulation cor-
tactin protein expression, a cytoskeletal and ZO-1–
interacting protein (4). Cortactin and Cx43 can be
coimmunoprecipitated, but whether this occurs via a
ZO-1 linker or a direct interaction between cortactin
and ZO-1 is not clear, and how cortactin expression or
organization may affect Cx43 is not known (41). In
addition to the potential modulation of Cx43 via a
STRIPAK-ERK1/2-cortactin signaling axis, Ser279/
282 of Cx43 are also direct targets of ERK1/2; however,
phosphorylation at these sites is typically inhibitory
and, thus, may not represent the primary mechanism
by which CCM3 regulates Cx43 via the STRIPAK
complex (42, 43).
The current study has also demonstrated that lesions of
ccm3+/2p532/2mice exhibit a progression frompermeable
vessels to hemorrhagic vessels, a finding that is consistent
with previous murine fCCM studies (44). Gd-DTPA
leakage occurs before hemorrhage, and permeable ves-
sels have a 100% probability of hemorrhaging in the fu-
ture.Histologic analysis confirmed that lesions are present
in ccm3+/2p532/2 mice in multiple stages of maturation:
permeable, nonhemorrhagic stage 0 and hemorrhagic
stage 1 and 2 lesions. Identifying a mechanism by which
the permeability and maturation of stage 0 lesions can be
blocked represents an opportunity to prevent additional
pathologies.
CONCLUSIONS
Our study demonstrates that Cx43 protein is aberrantly
up-regulated in developing CCM3 lesions before hemor-
rhage. In vitrodata suggest that Cx43GJs are instigators of
BBB breakdown by regulating ZO-1 localization and,
subsequently, limiting TJ formation and TJ transinter-
actions. The Cx43 GJ inhibitor, GAP27, blocked these
changes. How the loss of CCM3 regulates Cx43 GJ plaque
formation and signaling events that regulate Cx43–ZO-1
plaque formation should be the focus of future studies. In
addition, whether in vivo treatment of fCCM3 mice with
GAP27 can ameliorate Gd-DTPA leakage and subsequent
hemorrhage is of paramount importance to determine if
GAP27 or similar peptides may be candidate pharma-
ceutical options for patients with fCCM3. Of importance,
this is the first study toour knowledge todefinitively show
that GJs can regulate BBB permeability in a TJ-dependent
manner. Whether other mechanisms exist by which GJs
can regulate permeability (i.e., via GJIC itself) should be
further investigated.
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